June 12, 2013—Medicaid officials in three states have recently issued provider bulletins clarifying the procedures for billing 340B drugs used for fee for service (FFS) and managed care beneficiaries.
June 12, 2013—The Health Resources and Services Administration (HRSA) says Amgen’s decision to sell its biologic drug Neulasta at 340B pricing exclusively through specialty distributors “will not violate the 340B statute,” the agency has told both the association representing 340B hospitals and the 340B prime vendor. Neulasta is an expensive, man-made human protein used to [...]
June 7, 2013—Bayer HealthCare Pharmaceuticals is limiting distribution of its new intrauterine device (IUD) Skyla due to high demand and productions delays, the Office of Pharmacy Affairs (OPA) has announced. Under OPA policy, drug manufacturers can develop a limited allocation plan for 340B covered outpatient drugs when supply is inadequate to meet demand, so long [...]
May 31, 2013—The group that represents hospitals in the 340B drug discount program has asked the pharmaceutical manufacturer Amgen to withdraw its new requirement that all 340B purchases of the company’s drug Neulasta be made exclusively through specialty distribution channels. In a May 30 statement, Safety Net Hospitals for Pharmaceutical Access (SNHPA) said the policy [...]
May 31, 2013—The Department of Veteran Affairs (VA) and the Department of Defense (DOD) are paying different prices for the same prescription drugs, the Government Accountability Office (GAO) has found. However, the findings may not be that surprising considering the purchasing patterns of the two agencies, GAO researchers found.
May 23, 2013—The manufacturer of the only FDA-approved orphan drug for children with a rare hormone deficiency that causes short stature is limiting purchases due to an imminent halt in production. The Office of Pharmacy Affairs (OPA) posted the notice by Ipsen Biopharmaceuticals, the maker of the drug Increlex, on its website’s home page on [...]
May 17, 2013—About 25 million Americans will gain health coverage by 2023 under the Affordable Care Act (ACA) but about 31 million will remain without insurance, according to new projections from the nonpartisan Congressional Budget Office (CBO). The health coverage figures were included in CBO’s latest federal budget projections for the coming decade.
May 16, 2013—The long-awaited regulation to implement health care reform’s partial limit on 340B discounts for orphan drugs is back on hold. On May 8, the White House Office of Management and Budget (OMB) reported online that its review of the Health Resources and Services Administration’s (HRSA) proposed 340B orphan drug exclusion final rule had [...]
May 15, 2013—Drug manufacturer Mylan has mailed refunds to 340B providers for overcharges on all products sold by its Mylan Specialty subsidiary (formerly known as Dey Pharma) from late 1994 through late 2006. Last November, the Office of Pharmacy Affairs (OPA) posted a message from Mylan on its home page explaining that the company needed [...]
May 7, 2013—A federal district judge has ordered California to stop requiring 340B health care providers to “carve in” all Medicaid patients and to bill the state for 340B drugs given to such patients at actual acquisition cost (AAC). Acting in a case brought by the AIDS Healthcare Foundation (AHF), U.S. District Judge Manuel L. [...]